Evidence map›Paper›PMID 39820338›Full record

ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2025

Early versus late atrial fibrillation recurrence after pulsed field ablation: insights from the admIRE trial.

Luigi Di Biase, Vivek Y Reddy, Marwan Bahu, David Newton, Christopher F Liu, William H Sauer, Sandeep Goyal, Vivek Iyer, Devi Nair, Jose Osorio and 4 more

Registry-linked trialAbstract readMulticenter StudyComparative Study
In one paragraph

Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05293639 (Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05293639 nacompletednot on this map

Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System (AdmIRE)

TypeinterventionalSponsorBiosense Webster, Inc.Ran2022 to 2023Enrolled362ConditionsAtrial FibrillationArmsPulse Field Ablation
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pulsed field ablation for the interventional treatment of atrial fibrillation: a scientific statement of the European Heart Rhythm Association of the European Society of Cardiology, the Heart Rhythm Society, the Asia Pacific Heart Rhythm Society, the Latin American Heart Rhythm Society, and the Canadian Heart Rhythm Society.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Guideline
  2. Early recurrence of atrial tachyarrhythmia after catheter ablation and its associations with clinical outcomes, atrial fibrillation burden, and blanking period duration: a post hoc analysis of the CABANA trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  3. Trial
  4. Review
  5. Early recurrence after pulsed field ablation: a prognostic signal that challenges, but does not eliminate, the blanking period.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  6. Article
  7. Incidence and predictors of AF recurrence during long-term follow-up of patients after PF ablation for atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  8. The blanking interval after atrial fibrillation ablation: time for reassessment with pulsed field energy.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  9. Article
  10. Real-world strategies for pulsed field ablation using a variable-loop circular catheter: a compendium of best practices from early adopters.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026
    Article
  11. Article
  12. Controversy: the blanking period after atrial fibrillation ablation is needed and should be maintained.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
  13. Review
  14. A new basket player on the court: pulsed field ablation with a balloon-in-basket system for atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Luigi Di BiaseCardiac Arrhythmia Center, Division of Cardiology at the Montefiore Medical Center, Albert Einstein College of Medicine, 111 E 210 St., New York, NY 10467, USA.ORCID 0000-0001-6508-4047
Vivek Y ReddyHelmsley Electrophysiology Center, Mount Sinai Fuster Heart Hospital, New York, NY, USA.ORCID 0000-0002-5638-4993
Marwan BahuPhoenix Cardiovascular Research Group, Phoenix, AZ, USA.
David NewtonClinical Cardiac Electrophysiology Department, Memorial Health, Savannah, GA, USA.ORCID 0009-0002-3838-6386
Christopher F LiuCardiology Department, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY, USA.ORCID 0000-0001-8852-4551
William H SauerCardiac Arrhythmia Service, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0009-0006-8556-3612
Sandeep GoyalPiedmont Heart of Buckhead Electrophysiology, Piedmont Heart Institute, Atlanta, GA, USA.ORCID 0000-0001-6915-9835
Vivek IyerMarinHealth Cardiovascular Medicine, Marin Health Medical Center, Larkspur, CA, USA.
Devi NairHeart & Vascular Department, St. Bernards Medical Center & Arrhythmia Research Group, Jonesboro, AR, USA.ORCID 0000-0001-8253-947X
Jose OsorioHCA Florida Miami Electrophysiology - Cardiovascular Group, HCA Florida Miami, Miami, FL, USA.ORCID 0000-0001-7466-123X
Moussa MansourAtrial Fibrillation Program, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0003-3326-9973
Hugh CalkinsElectrophysiology Laboratory and Arrhythmia Service, Johns Hopkins Medical Institutions, Baltimore, MD, USA.ORCID 0000-0002-9262-9433
Oussama WazniCardiac Electrophysiology and Pacing, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0001-7115-7716
Andrea NataleTexas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, TX, USA.ORCID 0000-0001-6601-944X

Funding

Biosense Webster, Inc.
6 · The paper itself

Abstract

aimsStudies have shown correlations between early recurrence (ER) and late recurrence (LR) of atrial arrhythmia after ablation with thermal technologies. This admIRE trial (NCT05293639) subanalysis aims to analyse ER vs. LR in patients with paroxysmal atrial fibrillation (PAF) undergoing pulsed field ablation (PFA). METHODS AND

resultsPatients with symptomatic paroxysmal atrial fibrillation and ≥1 transtelephonic monitoring transmission during the blanking period were included (n = 169). ER was defined as documented recurrence in the blanking period (days 1-90), and LR as recurrence in the evaluation period (days 91-365). Freedom from 12-month recurrence was estimated using Kaplan-Meier method. A Cox proportional-hazards regression model, with ER as the primary factor, and adjusted for age, sex, and body mass index, was used to estimate hazard ratios (HRs) and 95% CI. ER was observed in 20.1% (31/169) of patients (66.1 ± 7.1 years, 35.5% female, 46.6 ± 48.4-month PAF history). Time to first documented ER was 49 (37-61) days. Occurrence of LR was 16.7% (23/138) in patients without ER, 71.0% (22/31) in those with ER, and 87.0% (20/23) in patients whose ER onset occurred within the first 2 months. Twelve-month freedom from documented recurrence was significantly lower in patients with ER at 29.0% (95% CI, 13.1-45.0%) vs. 82.5% (95% CI, 75.9-89.1%) in those without ER (adjusted HR, 7.9; 95% CI, 4.1-15.1; P < 0.001).

conclusionThis admIRE subanalysis demonstrated that PAF patients who experience ER after PFA are at a substantially higher risk for LR. The optimal duration of the blanking period post-PFA needs further assessments. CLINICALTRIALS.GOV IDENTIFIER: NCT05293639.

Indexed as

Atrial FibrillationCatheter AblationAgedFemaleHumansMaleMiddle AgedRecurrenceRisk FactorsTime FactorsTreatment OutcomeAblationAtrial fibrillationEarly recurrenceLate recurrencePulsed field ablationVaripulse

Identifiers

PMID39820338
PMCPMC11879039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.